KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Operating Leases (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Operating Leases for 7 consecutive years, with $653000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 74.59% year-over-year to $653000.0, compared with a TTM value of $653000.0 through Dec 2025, down 74.59%, and an annual FY2025 reading of $653000.0, down 74.59% over the prior year.
  • Operating Leases was $653000.0 for Q4 2025 at Esperion Therapeutics, down from $767000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $4.4 million in Q1 2024 and bottomed at $47000.0 in Q3 2022.
  • Average Operating Leases over 5 years is $1.7 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Operating Leases tumbled 96.42% in 2022, then surged 4259.57% in 2023.
  • Year by year, Operating Leases stood at $524000.0 in 2021, then increased by 26.91% to $665000.0 in 2022, then skyrocketed by 354.14% to $3.0 million in 2023, then decreased by 14.9% to $2.6 million in 2024, then plummeted by 74.59% to $653000.0 in 2025.
  • Business Quant data shows Operating Leases for ESPR at $653000.0 in Q4 2025, $767000.0 in Q3 2025, and $1.3 million in Q2 2025.